Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492933 | 0.87 | TMEM97 (0.45) | FKBP1AMEN1KMT2AGFERTMEM97 | |
| SCHEMBL5724804 | 0.82 | PREP (0.42) | MEN1KMT2AGFERHRH3ALDH1A1 | |
| SCHEMBL5730247 | 0.79 | GFER (0.45) | FKBP1AMEN1KMT2AGFERCTSL | |
| SCHEMBL7382767 | 0.76 | FKBP1A (0.53) | FKBP1AMEN1KMT2ACTSLKLK7 | |
| SCHEMBL28964197 | 0.76 | TSHR (0.52) | MEN1KMT2AGFERCTSLTMEM97 | |
| SCHEMBL28964198 | 0.76 | TSHR (0.52) | MEN1KMT2AGFERCTSLTMEM97 | |
| SCHEMBL5724709 | 0.76 | NPC1 (0.40) | HRH3ALDH1A1NPC1RAB9AELANE | |
| SCHEMBL6500495 | 0.74 | MGLL (0.41) | ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL20528094 | 0.74 | KDM1A (0.53) | FKBP1ACTSLKLK7ALDH1A1 | |
| SCHEMBL20522962 | 0.74 | KDM1A (0.53) | FKBP1ACTSLKLK7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246810-B1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO MCNEIL PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6518285-B2 | 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | OXA1L, RPS27L, RPS27 | FKBP1A 1813/4885MEN1 3697/4885KMT2A 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.